about
Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminusAdeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1Adeno-associated virus for cystic fibrosis gene therapyMorquio A syndrome: diagnosis and current and future therapiesStructure of AAV-DJ, a Retargeted Gene Therapy Vector: Cryo-Electron Microscopy at 4.5 Å ResolutionHeparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.Neuronal affinity of a C7C loop peptide identified through phage display.Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferIn vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.Directed evolution of adeno-associated virus for glioma cell transductionHeart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library.Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, and retroviral vector delivery systemsTherapies of mucopolysaccharidosis IVA (Morquio A syndrome).Purified feline and canine transferrin receptors reveal complex interactions with the capsids of canine and feline parvoviruses that correspond to their host rangesA nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculationIdentification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors.Gene therapy for proliferative ocular diseases.Recombinant adeno-associated virus vectors for gene therapy.Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).Intracellular trafficking of adeno-associated viral vectors.Versatility of gene therapy vectors through viruses.Adeno-associated virus vectors: potential applications for cancer gene therapy.Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications.p53 gene in treatment of hepatic carcinoma: status quo.Gene and cell therapy for heart failure.Cardiac gene therapy with SERCA2a: from bench to bedsideAntibody-mediated targeted gene transfer of helper virus-free HSV-1 vectors to rat neocortical neurons that contain either NMDA receptor 2B or 2A subunits.Engineered retroviral virus-like particles for receptor targeting.Comparative analysis of the transduction efficiency of five adeno associated virus serotypes and VSV-G pseudotype lentiviral vector in lung cancer cellsAntibody-mediated targeted gene transfer to NMDA NR1-containing neurons in rat neocortex by helper virus-free HSV-1 vector particles containing a chimeric HSV-1 glycoprotein C-staphylococcus A proteinAugmented transgene expression in transformed cells using a parvoviral hybrid vector.Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein.Engineered E. coli delivers therapeutic genes to the colonic mucosa.[Gene therapy as a treatment concept for inherited retinal diseases].Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.Fusion of Anthopleurin-B to AAV2 increases specificity of cardiac gene transfer.Preparation of poly(ethylene glycol)-introduced cationized gelatin as a non-viral gene carrier.Enhanced Targeted Gene Transduction: AAV2 Vectors Conjugated to Multiple Aptamers via Reducible Disulfide Linkages.A gene-fusion strategy for stoichiometric and co-localized expression of light-gated membrane proteins.
P2860
Q24563214-FDD6E392-97EC-44A3-8366-3006B0B650B0Q24634560-CB3E5DC4-4334-44D5-8388-B7564E125A1DQ26823156-87CF25F3-E63F-4AAF-A7B8-E7881FEDC471Q27014063-4BF8E62A-8395-4DDC-848B-643A7BD4A262Q27681347-9DC5077B-E96E-4000-9C10-91F8C22D4D30Q33248410-D05BBC99-9DB0-48A3-B8C4-4558DC55DC40Q33252514-7AB2A40E-E2F2-49B4-821F-B0764024AEC8Q33296224-1345159F-0D2E-4D3F-B86C-DB1CA56500F3Q33327474-0BF1BEB8-8E47-46D6-B6A7-71695587738DQ33484220-382011C2-7759-47A4-BE79-0AB13FBFED25Q33555864-8D9BF41A-AE34-4A11-B386-7A727845729EQ33821596-F7E4260C-B3C0-497E-AD72-58C7FBF3AFDEQ34545883-14B25C7B-9E92-43A6-ABE7-6C573F3AC1B3Q35024094-7BCADFE0-303A-4CC5-829B-888D2B732DAAQ35543174-F503AFBC-28A1-4D79-A4F6-68789ADCB52DQ35661179-88416E1B-AA57-4FDF-8EF3-DBC21B9A6255Q35712206-0EAFFDD6-CDD0-48CE-B075-32A86EEF4308Q35842653-A34EF793-4CF5-4B3C-BD46-250201F009F8Q35842668-57B4B41A-96DB-4C82-B4D8-EE6A1251ECFDQ35904461-4E463002-FE94-4C97-A04A-95C4267A91B7Q36097743-8E7485E6-3718-41BC-BB65-C5B56DA16A5CQ36150489-CA6F037F-5F28-47D0-BD78-6C2BFC12B5ACQ36165834-AA6B3663-65C2-4515-8B52-F48D8C6E4148Q36288920-216A8D11-1C76-4BA9-B90D-F81485AB27E2Q36764842-03CA92A1-99B9-4804-81E5-C261FF694A43Q37470623-750C593B-FBCF-49B9-B1A9-FA9F4EFED779Q37811189-4334ED09-ECAF-492D-80B0-7A64B0349180Q38532388-350C9A60-730B-40A8-9E15-D4F93D72EF20Q39077630-80680B16-2BEF-403C-8027-86679C84C8BEQ39180687-3B4C6267-C243-4D65-AA80-272E85293759Q39685068-60AFDBE1-FF06-4ACD-9CD9-21006BA5D386Q40023775-F82F88EE-5E6E-4395-BFB6-FEBBD6BDE8BEQ40402866-6665C31C-FFA6-49A1-8D78-7E69EF9A1CD0Q41458834-27A91FD8-6690-4632-BC52-218F230672DBQ41465719-347D1D14-BE0D-4654-A521-F15343745F54Q42203239-3CFA24AA-2536-44EE-B5AF-6B58DF68D63EQ45873143-846EB5CE-210C-4C4F-B9C2-202CB1D44696Q46862788-3C6CA1A7-10F6-43C5-B277-0B72924A2B3FQ47235611-17EB0132-C58E-4CAA-A880-DD7197411CE4Q48054791-49329B8E-D951-460B-988F-395BC19ABE92
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Receptor targeting of adeno-associated virus vectors.
@ast
Receptor targeting of adeno-associated virus vectors.
@en
type
label
Receptor targeting of adeno-associated virus vectors.
@ast
Receptor targeting of adeno-associated virus vectors.
@en
prefLabel
Receptor targeting of adeno-associated virus vectors.
@ast
Receptor targeting of adeno-associated virus vectors.
@en
P2093
P2860
P356
P1433
P1476
Receptor targeting of adeno-associated virus vectors.
@en
P2093
Huttner NA
P2860
P2888
P304
P356
10.1038/SJ.GT.3301976
P577
2003-07-01T00:00:00Z